Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis

Journal of Crohn's and Colitis

Volumn 8, Issue 8, 2014, Pages 775-788

  Algieri, Francesca ^a   Rodriguez Nogales, Alba ^a   Garrido Mesa, Natividad ^a   Zorrilla, Pedro ^a   Burkard, Natalie ^b   Pischel, Ivo ^b   Sievers, Hartwig ^b   Benedek, Birgit ^b   Feistel, Björn ^c   Walbroel, Bernd ^c   Rodriguez Cabezas, M Elena ^a   Galvez, Julio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b PhytoLab GmbH   (Germany)

^c Plantextrakt GmbH and Co KG   (Germany)

Author keywords

DSS mouse colitis; ; Intestine anti inflammatory activity; Serpylli herba; ; Thymus serpyllum; ; TNBS rat colitis;

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; DEXTRAN SULFATE; GAMMA INTERFERON; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE B4; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PLANT EXTRACT; SALAZOSULFAPYRIDINE; SERPYLLI HERBA EXTRACT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRIC PARAMETERS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMICAL ANALYSIS; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENTERITIS; EXPERIMENTAL COLITIS; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY INFILTRATE; INTESTINE INJURY; MEDIATOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; SERPYLLI HERBA; THYMUS (PLANT); ANIMAL CELL; BONE MARROW DERIVED MACROPHAGE; COLITIS; COLON; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MEGADOSE; ENZYME ACTIVITY; HISTOPATHOLOGY; LOW DRUG DOSE; MEDICINAL PLANT; PROTEIN EXPRESSION; RODENT MODEL; TISSUE SECTION; TREATMENT RESPONSE; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; PLANT EXTRACTS; RATS; RATS, WISTAR; THYMUS PLANT; TRINITROBENZENESULFONIC ACID;

EID: 84904515594     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.12.012     Document Type: Article

References (48)

1. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
2. McGuckin M.A., Eri R., Simms L.A., Florin T.H., Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009, 15:100-113.
3. Grisham M.B. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994, 344:859-861.
4. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
5. Siegel C.A. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther 2011, 33:23-32.
6. Weizman A.V., et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther 2012, 35:342-349.
7. Burgmann T., Rawsthorne P., Bernstein C.N. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use?. Am J Gastroenterol 2004, 99:889-893.
8. Singh U.P., et al. Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol 2012, 31:66-84.
9. Ke F., Yadav P.K., Ju L.Z. Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol 2012, 18:3-10.
10. Hanai H., Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009, 15:2087-2094.
11. Langmead L., et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004, 19:739-747.
12. Clarke J.O., Mullin G.E. A review of complementary and alternative approaches to immunomodulation. Nutr Clin Pract 2008, 23:49-62.
13. Braga P.C., Dal Sasso M., Culici M., Bianchi T., Bordoni L., Marabini L. Anti-inflammatory activity of thymol: inhibitory effect on the release of human neutrophil elastase. Pharmacology 2006, 77:130-136.
14. Bukovská A., Cikos S., Juhás S., Il'ková G., Rehák P., Koppel J. Effects of a combination of thyme and oregano essential oils on TNBS-induced colitis in mice. Mediators Inflamm 2007, 2007:23296.
15. Fachini-Queiroz F.C., et al. Effects of Thymol and Carvacrol, Constituents of Thymus vulgaris L. Essential Oil, on the Inflammatory Response. Evid Based Complement Alternat Med 2012, 2012:657026.
16. Komes D., Belščak-Cvitanović A., Horžić D., Rusak G., Likić S., Berendika M. Phenolic composition and antioxidant properties of some traditionally used medicinal plants affected by the extraction time and hydrolysis. Phytochem Anal 2011, 22:172-180.
17. De Oliveira N.C., et al. Rosmarinic acid as a protective agent against genotoxicity of ethanol in mice. Food Chem Toxicol 2012, 50:1208-1214.
18. Karmokar A., Marczylo T.H., Cai H., Steward W.P., Gescher A.J., Brown K. Dietary intake of rosmarinic acid by Apc(Min) mice, a model of colorectal carcinogenesis: levels of parent agent in the target tissue and effect on adenoma development. Mol Nutr Food Res 2012, 56:775-783.
19. Elson C.O., Sartor R.B., Tennyson G.S., Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109:1344-1367.
20. Camuesco D., et al. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm Bowel Dis 2005, 11:265-271.
21. Bell C.J., Gall D.G., Wallace J.L. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol Gastrointest Liver Physiol 1995, 268:G622-G630.
22. Melgar S., Karlsson A., Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1328-G1338.
23. Bailón E., et al. UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis. Inflamm Bowel Dis 2008, 14:888-897.
24. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87:1344-1350.
25. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 1985, 113:548-555.
26. Comalada M., et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol 2005, 35:584-592.
27. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite and [15N]nitrate in biological fluid. Anal Biochem 1982, 126:131-138.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
29. Arafa H.M., Hemeida R.A., El-Bahrawy A.I., Hamada F.M. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem Toxicol 2009, 47:1311-1317.
30. Nielsen O.H., Munck L.K. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:160-170.
31. Kelm M.A., Nair M.G., Strasburg G.M., DeWitt D.L. Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine 2000, 7:7-13.
32. Zheng W., Wang S.Y. Antioxidant activity and phenolic compounds in selected herbs. J Agric Food Chem 2001, 49:5165-5170.
33. Pavel M., Vostinaru O., Mogosan C., Ghibu S. Phytochemical and pharmacological research on some extracts obtained from Serpylli herba. Farmacia 2011, 59:77-84.
34. Ruela-de-Sousa R.R., Fuhler G.M., Blom N., Ferreira C.V., Aoyama H., Peppelenbosch M.P. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis. 2010, 1:e19.
35. Pavlick K.P., et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002, 33:311-322.
36. Camuesco D., et al. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol 2004, 143:908-918.
37. Garrido-Mesa N., et al. The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. Pharmacol Res 2011, 63:308-319.
38. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984, 86:453-460.
39. Sheibanie A.F., et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23/IL-17 axis. J Immunol 2007, 178:8138-8147.
40. Eliakim R., Karmeli F., Chorev M., Okon E., Rachmilewitz D. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. Scand J Gastroenterol 1992, 27:968-972.
41. Itzkowitz S.H. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006, 35:553-571.
42. Alex P., et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009, 15:341-352.
43. Camuesco D., et al. The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol 2012, 165:729-740.
44. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
45. Abraham C., Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1090-1100.
46. Liu Z.J., Yadav P.K., Su J.L., Wang J.S., Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2009, 15:5784-5788.
47. Lindsay J.O., Hodgson H. Review article: the immunoregulatory cytokine interleukin-10: a therapy for Crohn's disease?. Aliment Pharmacol Ther 2001, 15:1709-1716.
48. Baba S., Osakabe N., Natsume M., Terao J. Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid. Life Sci 2004, 75:165-178.